ScinoPharm Taiwan, Ltd.

TWSE:1789 Stock Report

Market Cap: NT$17.8b

ScinoPharm Taiwan Past Earnings Performance

Past criteria checks 5/6

ScinoPharm Taiwan has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 3.3% per year. ScinoPharm Taiwan's return on equity is 3.8%, and it has net margins of 11.4%.

Key information

8.3%

Earnings growth rate

8.3%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate3.3%
Return on equity3.8%
Net Margin11.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 17
ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

Apr 04
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Mar 14
A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

Feb 21
Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

Jan 25
ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Jan 04
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Dec 14
Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Nov 23
Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Revenue & Expenses Breakdown

How ScinoPharm Taiwan makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TWSE:1789 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,493399547387
30 Jun 243,428403558334
31 Mar 243,421385551356
31 Dec 233,186287544358
30 Sep 233,079231522355
30 Jun 233,124261523333
31 Mar 233,175318533298
31 Dec 223,264353574271
30 Sep 222,968305613264
30 Jun 222,917254658274
31 Mar 222,859230681265
31 Dec 212,762243686306
30 Sep 212,917198681276
30 Jun 213,021266692301
31 Mar 213,182337708288
31 Dec 203,083282696246
30 Sep 203,028323684243
30 Jun 202,954279682232
31 Mar 202,663174662235
31 Dec 192,893217671238
30 Sep 192,933262681296
30 Jun 193,067312672263
31 Mar 193,435386675308
31 Dec 183,524443671313
30 Sep 183,560410655285
30 Jun 183,591434660317
31 Mar 183,458388650305
31 Dec 173,516422677314
30 Sep 173,624508684294
30 Jun 173,767567672283
31 Mar 173,929657675276
31 Dec 164,031659658280
30 Sep 164,059707649305
30 Jun 164,050736647309
31 Mar 163,998694644315
31 Dec 153,955635603324
30 Sep 153,775445589331
30 Jun 153,795371591355
31 Mar 153,980432595399
31 Dec 144,098484625416
30 Sep 144,572744694455
30 Jun 144,809875698451
31 Mar 145,0001,089712417

Quality Earnings: 1789 has high quality earnings.

Growing Profit Margin: 1789's current net profit margins (11.4%) are higher than last year (7.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1789's earnings have grown by 8.3% per year over the past 5 years.

Accelerating Growth: 1789's earnings growth over the past year (72.7%) exceeds its 5-year average (8.3% per year).

Earnings vs Industry: 1789 earnings growth over the past year (72.7%) exceeded the Pharmaceuticals industry 11.9%.

Return on Equity

High ROE: 1789's Return on Equity (3.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 20:06
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ScinoPharm Taiwan, Ltd. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ti-Rung HuangBarclays
Pinghan HsiehCapital Securities Corporation
Christine WangDaiwa Securities Co. Ltd.